Hypera Says It Can Follow Potential Further Price Cuts for GLP1 Medicines
Hypera’s president said the company has room to follow potential further price reductions for GLP1 medicines, adding, “We will be competitive in this market.”
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.